Nanotheranostics for personalized medicine

Expert Review of Molecular Diagnostics

Volumn 13, Issue 3, 2013, Pages 257-269

  Kim, Tae Hyung ^a   Lee, Seulki ^a   Chen, Xiaoyuan ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

chemotherapy; drug delivery; molecular imaging; molecular profiling; nanotechnology; nanotheranostics; prodrugs

Indexed keywords

ASPARAGINASE MACROGOL; CAMPTOSAW; CETUXIMAB; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; GOLD NANOPARTICLE; IBRITUMOMAB TIUXETAN; IRINOTECAN; MAGNETIC NANOPARTICLE; PACLITAXEL; POLYMER; SMALL INTERFERING RNA; TAMOXIFEN; TAMOXIFEN CITRATE; TRASTUZUMAB; UNCLASSIFIED DRUG; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RADIOTHERAPY; COLORECTAL CANCER; HUMAN; KAPOSI SARCOMA; LIPOSOMAL GENE DELIVERY SYSTEM; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; METASTASIS; MULTIMODALITY CANCER THERAPY; NANOMEDICINE; NANOTECHNOLOGY; NANOTHERANOSTIC; OVARY CANCER; PERSONALIZED MEDICINE; REVIEW;

ANIMALS; DRUG CARRIERS; HUMANS; INDIVIDUALIZED MEDICINE; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; PRODRUGS; TUMOR MARKERS, BIOLOGICAL;

EID: 84876130374     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.13.15     Document Type: Review

References (94)

1. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11(3), 191-200 (2012
2. Hamburg MA, Collins FS. The path to personalized medicine. N. Engl. J. Med. 363(4), 301-304 (2010
3. Chen XS. Introducing Theranostics Journal - from the Editor-in-Chief. Theranostics 1, 1-2 (2011
4. Chen XS. One year after a successful start of theranostics. Theranostics 2(1), 1-2 (2012
5. Swierczewska M, Liu G, Lee S, Chen X. High-sensitivity nanosensors for biomarker detection. Chem. Soc. Rev. 41(7), 2641-2655 (2012
6. Chikkaveeraiah BV, Bhirde AA, Morgan NY, Eden HS, Chen X. Electrochemical immunosensors for detection of cancer protein biomarkers. ACS Nano. 6(8), 6546-6561 (2012
7. Shao H, Min C, Issadore D et al. Magnetic Nanoparticles and microNMR for diagnostic applications. Theranostics 2(1), 55-65 (2012
8. Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv. Drug Deliv. Rev. 58(14), 1456-1459 (2006
9. Swierczewska M, Lee S, Chen X. Moving theranostics from bench to bedside in an interdisciplinary research team. Ther. Deliv. 2(2), 165-170 (2011
10. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv. Drug Deliv. Rev. 62(11), 1064-1079 (2010
11. Hulteen JC, Treichel DA, Smith MT, Duval ML, Jensen TR, Van Duyne RP. Nanosphere lithography: size-tunable silver nanoparticle and surface cluster arrays. J. Phy. Chem. B 103(19), 3854-3863 (1999
12. Haynes CL. Nanosphere lithography: a versatile nanofabrication tool for studies of size-dependent nanoparticle optics. J. Phys. Chem. 105(24), 5599-5611 (2001
13. Grzelczak M, Perez-Juste J, Mulvaney P, Liz-Marzan LM. Shape control in gold nanoparticle synthesis. Chem. Soc. Rev. 37(9), 1783-1791 (2008
14. Rozenberg BA, Tenne R. Polymer-assisted fabrication of nanoparticles and nanocomposites. Progress Polymer Sci. 33(1), 40-112 (2008
15. Akhter S, Ahmad MZ, Ahmad FJ, Storm G, Kok RJ. Gold nanoparticles in theranostic oncology: current state-of-theart. Expert Opin. Drug Deliv. 9(10), 1225-1243 (2012
16. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv. Drug Deliv. Rev. 64(13), 1394-1416 (2012
17. Wang LS, Chuang MC, Ho JA. Nanotheranostics - a review of recent publications. Int. J. Nanomedicine 7, 4679-4695 (2012
18. Wang R, Billone PS, Mullett WM. Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials. J. Nanomat. doi:10.1155/2013/629681 (2013) (Epub ahead of print
19. Choi KY, Jeon EJ, Yoon HY et al. Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials 33(26), 6186-6193 (2012
20. Liotta L, Petricoin E. Molecular profiling of human cancer. Nat. Rev. Genet. 1(1), 48-56 (2000
21. Sadee W, Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum. Mol. Genet. 14(Spec. no. 2), R207-R214 (2005
22. Vogenberg FR, Isaacson Barash C, Pursel M. Personalized medicine: part 1: evolution and development into theranostics. P. T. 35(10), 560-576 (2010
23. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 14(3), 154-169 (2008
24. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 64, 15-29 (2013
25. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286(5439), 531-537 (1999
26. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769), 503-511 (2000
27. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747-752 (2000
28. Bittner M, Meltzer P, Chen Y et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406(6795), 536-540 (2000
29. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412(6849), 822-826 (2001
30. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23(9), 1147-1157 (2005
31. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19(53), 6102-6114 (2000
32. Pegram MD, Lipton A, Hayes DF et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16(8), 2659-2671 (1998
33. Dowsett M, Bartlett J, Ellis IO et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J. Pathol. 199(4), 418-423 (2003
34. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009
35. Xing Y, Chaudry Q, Shen C et al. Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat. Protoc. 2(5), 1152-1165 (2007
36. Alivisatos AP. Semiconductor clusters, nanocrystals, and quantum dots. Science 271(5251), 933-937 (1996
37. Zhang Y, Wang TH. Quantum dot enabled molecular sensing and diagnostics. Theranostics 2(7), 631-654 (2012
38. Eckelman WC, Reba RC, Kelloff GJ. Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. Drug Discov. Today 13(17-18), 748-759 (2008
39. Velikyan I. Molecular imaging and radiotherapy: theranostics for personalized patient management. Theranostics 2(5), 424-426 (2012
40. Groves AM, Win T, Haim SB, Ell PJ. Non-[18F]FDG PET in clinical oncology. Lancet Oncol. 8(9), 822-830 (2007
41. Cai W, Chen X. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med. Chem. 6(5), 407-428 (2006
42. Niu G, Chen X. Why integrin as a primary target for imaging and therapy. Theranostics 1, 30-47 (2011
43. Ye Y, Chen X. Integrin targeting for tumor optical imaging. Theranostics 1, 102-126 (2011
44. Zhang F, Huang X, Zhu L et al. Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials 33(21), 5414-5422 (2012
45. Xie J, Chen K, Lee HY et al. Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. J. Am. Chem. Soc. 130(24), 7542-7543 (2008
46. Tan M, Lu ZR. Integrin targeted MR imaging. Theranostics 1, 83-101 (2011
47. Chin FT, Shen B, Liu S et al. First experience with clinical-grade ([18F] FPP(RGD2): an automated multi-step radiosynthesis for clinical PET studies. Mol. Imaging Biol. 14(1), 88-95 (2012
48. Gao H, Lang L, Guo N et al. PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTAPRGD2. Eur. J. Nucl. Med. Mol. Imaging 39(4), 683-692 (2012
49. Jacobson O, Zhu L, Niu G et al. MicroPET imaging of integrin avb3 expressing tumors using 89Zr-RGD peptides. Mol. Imaging Biol. 13(6), 1224-1233 (2011
50. Beer AJ, Kessler H, Wester HJ, Schwaiger M. PET imaging of integrin aVb3 expression. Theranostics 1, 48-57 (2011
51. Cai W, Shin DW, Chen K et al. Peptidelabeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 6(4), 669-676 (2006
52. Mornet S, Vasseur S, Grasset F, Duguet E. Magnetic nanoparticle design for medical diagnosis and therapy. J. Mater. Chem. 14(14), 2161-2175 (2004
53. Bulte JW, Brooks RA, Moskowitz BM, Bryant LH Jr, Frank JA. Relaxometry and magnetometry of the MR contrast agent MION-46L. Magn. Reson. Med. 42(2), 379-384 (1999
54. Xie J, Jon S. Magnetic nanoparticle-based theranostics. Theranostics 2, 122-124 (2012
55. Guo N, Lang L, Gao H et al. Quantitative analysis and parametric imaging of (18) F-labeled monomeric and dimeric RGD peptides using compartment model. Mol. Imaging Biol. 14(6), 743-752 (2012
56. Lee S, Xie J, Chen X. Activatable molecular probes for cancer imaging. Curr. Top. Med. Chem. 10(11), 1135-1144 (2010
57. Lee S, Xie J, Chen X. Peptide-based probes for targeted molecular imaging. Biochemistry 49(7), 1364-1376 (2010
58. Zhu L, Xie J, Swierczewska M et al. Real-time video imaging of protease expression in vivo. Theranostics 1, 18-27 (2011
59. Tyagi S, Kramer FR. Molecular beacons: probes that fluoresce upon hybridization. Nat. Biotechnol. 14(3), 303-308 (1996
60. Kim K, Lee M, Park H et al. Cell-permeable and biocompatible polymeric nanoparticles for apoptosis imaging. J. Am. Chem. Soc. 128(11), 3490-3491 (2006
61. Lee S, Choi KY, Chung H et al. Real time, high resolution video imaging of apoptosis in single cells with a polymeric nanoprobe. Bioconjug. Chem. 22(2), 125-131 (2011
62. Huang X, Swierczewska M, Choi KY et al. Multiplex imaging of an intracellular proteolytic cascade by using a broad-spectrum nanoquencher. Angew. Chem. Int. Ed. Engl. 51(7), 1625-1630 (2012
63. El-Deiry WS, Sigman CC, Kelloff GJ. Imaging and oncologic drug development. J. Clin. Oncol. 24(20), 3261-3273 (2006
64. Kelloff GJ, Krohn KA, Larson SM et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin. Cancer Res. 11(22), 7967-7985 (2005
65. Swierczewska M, Lee S, Chen X. Inorganic nanoparticles for multimodal molecular imaging. Mol. Imaging 10(1), 3-16 (2011
66. Xiao Y, Hong H, Matson VZ et al. Gold nanorods conjugated with doxorubicin and cRGD for combined anticancer drug delivery and PET imaging. Theranostics 2(8), 757-768 (2012
67. Jang B, Choi Y. Photosensitizer-conjugated gold nanorods for enzyme-activatable fluorescence imaging and photodynamic therapy. Theranostics 2(2), 190-197 (2012
68. Lee S, Cha EJ, Park K et al. A near-infrared- fluorescence-quenched gold-nanoparticle imaging probe for in vivo drug screening and protease activity determination. Angew. Chem. Int. Ed. Engl. 47(15), 2804-2807 (2008
69. López-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 7(10), 800-808 (2007
70. Rautio J, Kumpulainen H, Heimbach T et al. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7(3), 255-270 (2008
71. Choi KY, Swierczewska M, Lee S, Chen X. Protease-activated drug development. Theranostics 2(2), 156-178 (2012
72. Mansour AM, Drevs J, Esser N et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 63(14), 4062-4066 (2003
73. Rautio J, Kumpulainen H, Heimbach T et al. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7(3), 255-270 (2008
74. Habibollahi P, Figueiredo JL, Heidari P et al. Optical imaging with a cathepsin B activated probe for the enhanced detection of esophageal adenocarcinoma by dual channel fluorescent upper GI endoscopy. Theranostics 2(2), 227-234 (2012
75. Yhee JY, Kim SA, Koo H et al. Optical imaging of cancer-related proteases using near-infrared fluorescence matrix metalloproteinase-sensitive and cathepsin B-sensitive probes. Theranostics 2(2), 179-189 (2012
76. Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev. Mol. Cell Biol. 2(8), 589-598 (2001
77. Sinha AA, Wilson MJ, Gleason DF, Reddy PK, Sameni M, Sloane BF. Immunohistochemical localization of cathepsin B in neoplastic human prostate. Prostate 26(4), 171-178 (1995
78. Roshy S, Sloane BF, Moin K. Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev. 22(2-3), 271-286 (2003
79. Doronina SO, Toki BE, Torgov MY et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21(7), 778-784 (2003
80. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr. Opin. Chem. Biol. 13(3), 235-244 (2009
81. Gullotti E, Yeo Y. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol. Pharm. 6(4), 1041-1051 (2009
82. Hatakeyama H, Akita H, Kogure K et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther. 14(1), 68-77 (2007
83. Lee JH, Lee K, Moon SH, Lee Y, Park TG, Cheon J. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew. Chem. Int. Ed. Engl. 48(23), 4174-4179 (2009
84. Kim T, Huh Y-M, Haam S, Lee K. Activatable nanomaterials at the forefront of biomedical sciences. J. Mater. Chem. 20(38), 8194-8206 (2010
85. Derfus AM, von Maltzahn G, Harris TJ et al. Remotely triggered release from magnetic nanoparticles. Adv. Mater. 19(22), 3932-3936 (2007
86. Kim DH, Rozhkova EA, Ulasov IV et al. Biofunctionalized magnetic-vortex microdiscs for targeted cancer-cell destruction. Nat. Mater. 9(2), 165-171 (2010
87. Zhao Q, Wang L, Cheng R et al. Magnetic nanoparticle-based hyperthermia for head and neck cancer in mouse models. Theranostics 2, 113-121 (2012
88. Lim CK, Shin J, Lee YD et al. Phthalocyanine-aggregated polymeric nanoparticles as tumor-homing near-infrared absorbers for photothermal therapy of cancer. Theranostics 2(9), 871-879 (2012
89. Melancon MP, Zhou M, Li C. Cancer theranostics with near-infrared lightactivatable multimodal nanoparticles. Acc. Chem. Res. 44(10), 947-956 (2011
90. Yang K, Hu L, Ma X et al. Multimodal imaging guided photothermal therapy using functionalized graphene nanosheets anchored with magnetic nanoparticles. Adv. Mater. Weinheim 24(14), 1868-1872 (2012
91. Chalise P, Batzler A, Abo R, Wang L, Fridley BL. Simultaneous analysis of multiple data types in pharmacogenomic studies using weighted sparse canonical correlation analysis. OMICS 16(7-8), 363-373 (2012
92. Korwar AM, Bhonsle HS, Ghole VS, Gawai KR, Koppikar CB, Kulkarni MJ. Proteomic profiling and interactome analysis of ER-positive/HER2/neu negative invasive ductal carcinoma of the breast: towards proteomics biomarkers. OMICS 17(1), 27-40 (2013
93. US FDA approves Adcetris to treat two types of lympoma (2011). www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm268781.htm
94. US FDA Drug safety communication: new boxed warning and contraindication for Adcetris (brentuximab vedotin) (2012). www.fda.gov/Drugs/DrugSafety/ ucm287668.htm#data